Malmberg K, Yusuf S, Gerstein HC et al. Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non-Q-Wave Myocardial Infarction Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation, 2000, 102: 1014-1019.
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. The Emerging риск Factors Collaboration. Lancet, 2010, 375(9733): 2215-2222.
Рудакова Л.Е., Беляева Ю.Б., Рахматуллов Ф.К, Бондаренко Л.А., Ушакова С.В. Особенности течения фатального инфаркта миокарда у больных сахарным диабетом 2 типа. Медицинские науки, Клиническая медицин, 2001, 2(18): 117. / Rudakova L.E., Belyaeva Y.B., Rakhmatullov F.K., Bondarenko L.A., Ushakova S.V. Peculiarities of fatal myocardial infarction course in type 2 diabetes mellitus patients. Meditsinskiye Nauki, Klinicheskaya Meditsina, 2011, 2 (18): 117.
Александров А. А. и др. Сахарный диабет и ишемическая болезнь сердца: поиски решения. Сахарный диабет, 2005, 3: 34-38. / Alexandrov A.A. et al. Diabetes mellitus and ischemic heart disease: search of solution. Sakharny Diabet, 2005, 3: 34-38.
Van den Berghe G, Wouters P, Weekers Faet al. Intensive insulin therapy in critically ill patients. N Engl J Med, 2001, 345(19): 1359-1367.
Malmberg К, Rydén L, Efendic S et al. Randomized Trial of Insulin-Glucose Infusion Followed by Subcutaneous Insulin Treatment in Diabetic Patients With Acute Myocardial Infarction (DIGAMI Study): Effects on Mortality at 1 Year. J Am Coll Card, 1995, 26: 57-65.
Angeli F, Reboldi G, Poltronieri C et al. Hyperglycemia in acute coronary syndromes: from mechanisms to prognostic implications. Adv Cardiovasc Dis, 2015, 9(6): 412-424.
Turnbull FR, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 2009, 52(1): 2288-2298.
Singh K, Hibbert B, Singh B et al. Meta-analysis of admission hyperglycaemia in acute myocardial infarction patients treated with primary angioplasty: a cause or a marker of mortality. Eur Heart J Cardiovasc Pharmacother, 2015, 1: 220-228.
Birkhead J, Weston C, Timmis A, Chen R. The effects of intravenous insulin infusions on early mortality for patients with acute coronary syndromes who present with hyperglycaemia: A matched propensity analysis using data from the MINAP database 2008- 2012. Eur Heart J: Acute Cardiovascular Care, 2015, 4(4): 344-352.
Goyal A, Mehta SR, Díaz R et al., Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction. Circulation, 2009, 120: 2429-2437.
Kosiborod M, Inzucchi SE, Goyal A et al. Relationship Between Spontaneous and Iatrogenic Hypoglycemia and Mortality in Patients Hospitalized With Acute Myocardial Infarction. JAMA, 2009, 301(15): 1556-1564.
Siegelaar KL, Jacober SJ, Devries JH. A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction A reanalysis of the HEART2D study. Diabetes Care, 2011, 34(4): 855-857.
Zhang X, Xu X, Jiao X et al. The Effects of Glucose Fluctuation on the Severity of Coronary Artery Disease in Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2013, Article ID 576916, 6 pages http://dx.doi.org/10.1155/2013/576916..
DOI: 10.1155/2013/576916
Su G, Mi S-H, Tao H. Impact of Admission Glycemic Variability, Glucose, and Glycosylated Hemoglobin on Major Adverse Cardiac Events After Acute Myocardial Infarction. Diabetes Care, 2013, 36: 1026-1032.
Bond А. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proc (Bayl Univ Med Cent), 2006, 19: 281-284.
Plutzky J. The Incretin Axis in Cardiovascular Disease. Circulation, 2011, 124: 2285-2289.
Ryan D and Acosta A. GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond. Obesity, 2015, 23(6): 1119-1129.
Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med, 2005, 143: 559-569.
Irace C, Fiorentino R, Carallo C, Scavelli F, Gnasso A. Exenatide Improves Glycemic Variability Assessed by Continuous Glucose Monitoring in Subjects with Type 2 Diabetes. Diabetes technology & therapeutics, 2011, 13(12): 1261-1263.
Lønborg J, Vejlstrup N, Kelbæk H et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J, 2012, 33(12): 1491-1499.
Monji A et al. Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am J Physiol Heart Circ Physiol, 2013, 305: 295-304.
Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation, 2004, 109(8): 962-965.
Национальные рекомендации по диагностике и лечению пациентов с острым инфарктом миокарда с повышением сегмента ST на ЭКГ. 1-й выпуск 2007. Кардиоваскулярная терапия и профилактика. Приложение 1, 2007, 6(8): 415- 500. / National Recommendations on Diagnostics and Therapy of Patients with Acute Myocardial Infarction with ST segment elevation on ECG. Edition 1, 2007. Kardiovaskulyarnaya terapiya i profilaktika. Appendix I, 2007, 6 (8): 415-500.
Стандарты специализированной помощи при сахарном диабете. Под ред. Дедова И.И., Шестаковой М.В. 7-й выпуск. Сахарный диабет, 2015, 18(1S): 1-112. / Standards of specialized aid for diabetes mellitus. Ed. by Dedova I.I., Shestakova M.V., Ed.7. Sakharny Diabet, 2015, 18 (1S): 1-112.
NICE-SUGAR study investigators: Intensive versus conventional glucose control in critically ill patients. NEJM, 2010, 360(13): 1283-1295.
Krinsley JS. Glycemic variability: A strong independent predictor of mortality in critically ill patients. Critical Care Medicine, 2008, 36(11): 3008-3013. doi: 10.1097/CCM.0b013e31818b38d2]..
DOI: 10.1097/CCM.0b013e31818b38d2]
Donati A, Damiani E, Domizi R et al. Glycaemic variability, infections and mortality in a medical- surgical intensive care unit. Crit Care Resusc, 2014 Mar, 16(1): 13-23.
Krinsley JS, Preiser JC. Time in blood glucose range 70 to 140 mg/dl >80[%] is strongly associated with increased survival in non-diabetic critically ill adults. Crit. Care, 2015, 19: 79.
Бабенко А.Ю., Красильникова Е.И., Лихоносов Н.П., Лихоносова А.П., Гринева Е.Н. Влияние различных групп сахароснижающих препаратов на вариабельность гликемии у больных сахарным диабетом 2 типа, клиническое значение. Сахарный диабет, 2014, 4: 72-80. / Babenko A.Y., Krasilnikova E.I., Likhonosov N.P., Likhonosova A.P., Grineva E.N. Effect of various groups of sugarreducing drugs on glycemia variability in type 2 diabetes mellitus, clinical value. Sakharny Diabet, 2014, 4 : 72-80.
Rizzo MR, Barbieri M, Marfella R, Paolisso G.Reduction of Oxidative Stress and inflammation by Blunting Daily Acute Glucose Fluctuations in PatientsWith Type 2 Diabetes. Role of dipeptidyl peptidase-IV inhibition. Diabetes Care, 2012, 35(10): 2076-2082. doi: 10.2337/dc12-0199.
DOI: 10.2337/dc12-0199
Lin C-C, Li C-I, Yang S-Y, Liu C-S, Chen C-C, Fuh MM-T et al. Variation of Fasting Plasma Glucose: A Predictor of Mortality in Patients with Type 2 Diabetes. The American Journal of Medicine, 2012, 125(4): 416-418. doi: 10.1016/j.amjmed.2011.07.027..
DOI: 10.1016/j.amjmed.2011.07.027
Anagnostis P, Athyros VG, Adamidou F et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab, 2011, 13: 302-312.
Hattori Y, Jojima T, Tomizawa A et al. A glucagon- like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia, 2010, 53: 2256-2263.
Zhao TC. Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection. Cardiovasc Diabetol, 2013, 12: 90.
Burgmaier M, Heinrich C, Marx N. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuumin diabetes? Diabet Med, 2013, 30: 289-299.
Богова О.Т., Чукаева И.И. Инфаркт миокарда. Воспаление и прогноз. Российский кардиологический журнал, 2003, 4. http://medi. ru/doc/6630421.htm. / Bogova O.T., Chukaeva I.I. Myocardial infarction. Inflammation and forecast. Rossiysky Kardiologichesky Zhurnal, 2003, 4. http://medi.ru/doc/6630421.htmhttp://medi
Богова О.Т., Чукаева И.И. Инфаркт миокарда. Воспаление и прогноз. Российский кардиологический журнал, 2003, 4. http://medi. ru/doc/6630421.htm. / Bogova O.T., Chukaeva I.I. Myocardial infarction. Inflammation and forecast. Rossiysky Kardiologichesky Zhurnal, 2003, 4. http://medi.ru/doc/6630421.htmhttp://medi.ru/doc/6630421.htm
Antman EM, Fox KM. Guidelines for the diagnosis and management of unnstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum. Am. Heart J., 2000 Mar, 139(3): 461-75.
Williams ES, Shah SJ, Ali S et al. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail, 2008 January, 10(1): 63-69.
Hudson MP, Christenson RH, Newby LK. Cardiac markers: point of care testing. Clin. Chim. Acta., 1999 Jun 30, 284(2): 223-37.